PHAXIAM Therapeutics and Vetophage announce a long-term phage and endolysin research partnership

PHAXIAM Therapeutics and Vetophage, a Lyon-based company specialised in phage therapy for animal health, signed a long-term strategic research partnership to combine their expertise in discovering new phages and phage-derived proteins (endolysins) against antimicrobial resistance. The agreement gives PHAXIAM exclusive licensing options on specified phages and endolysins for human health from the Vetophage platform.